Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

LL-Z1271alpha: an interleukin-1beta production inhibitor.

K Ichikawa1, T Inagaki, H Kachi-Tonai

  • 1Exploratory Medicinal Sciences, PGRD, Nagoya Laboratories, Pfizer Pharmaceuticals Inc., 5-Gochi Taketoyo-cho, Chita-gun, Aichi 470-2393, Japan. katsuomi ichikawa@japan.pfizer.com

Biochemical and Biophysical Research Communications
|August 25, 2001
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Periodate oxidized ATP (oATP) reduces hyperalgesia in mice: involvement of P2X7 receptors and implications for therapy.

International journal of immunopathology and pharmacology·2008
Same author

New pyrrolizidinone antibiotics CJ-16,264 and CJ-16,367.

The Journal of antibiotics·2002
Same author

Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors.

The Journal of pharmacology and experimental therapeutics·2001
Same author

ATP acts as an agonist to promote stimulus-induced secretion of IL-1 beta and IL-18 in human blood.

Journal of immunology (Baltimore, Md. : 1950)·2000
Same author

Altered cytokine production in mice lacking P2X(7) receptors.

The Journal of biological chemistry·2000
Same author

Identification, characterization, and crystal structure of the Omega class glutathione transferases.

The Journal of biological chemistry·2000

LL-Z1271alpha, a fungal metabolite, effectively reduces interleukin-1beta (IL-1beta) production in both human blood and mouse models. This compound inhibits IL-1beta via a novel mechanism, distinct from known pathways.

Area of Science:

  • Immunology
  • Pharmacology
  • Microbiology

Background:

  • Interleukin-1beta (IL-1beta) is a key pro-inflammatory cytokine.
  • Dysregulation of IL-1beta is implicated in various inflammatory diseases.
  • Novel therapeutic agents targeting IL-1beta production are of significant interest.

Purpose of the Study:

  • To investigate the effect of the fungal metabolite LL-Z1271alpha on IL-1beta production.
  • To elucidate the mechanism of action of LL-Z1271alpha in inhibiting IL-1beta.

Main Methods:

  • In vitro studies using lipopolysaccharide (LPS)-stimulated human whole blood.
  • In vivo studies involving oral administration of LL-Z1271alpha to LPS-challenged mice.
  • Assays to measure IL-1beta levels and assess effects on caspase-1, ATP-induced release, and lysosomotrophic pathways.

Related Experiment Videos

Main Results:

  • LL-Z1271alpha demonstrated dose-dependent inhibition of IL-1beta production in human whole blood.
  • Oral administration of LL-Z1271alpha significantly reduced IL-1beta levels in the peritoneal cavity of mice.
  • The inhibitory activity of LL-Z1271alpha was not attributed to effects on caspase-1, ATP-induced release, or lysosomotrophic mechanisms.

Conclusions:

  • LL-Z1271alpha is a potent inhibitor of IL-1beta production.
  • LL-Z1271alpha acts through a novel mechanism, offering a potential new therapeutic strategy for inflammatory conditions.
  • Further research into LL-Z1271alpha's unique inhibitory pathway is warranted.